Anticoagulants Market Analysis

Anticoagulants Market Analysis

Based on the drug category, the anticoagulants market revenue from the Factor Xa inhibitor segment will reach USD 58.4 billion by 2032. High availability of Factor Xa inhibitors globally is contributing to segment growth. These drugs can lower the risk of stroke and venous thrombosis. Additionally, people taking them do not require frequent blood tests.
 

With respect to application, the anticoagulants market from coronary heart disease segment was worth over USD 21.8 billion in 2022. Growing prevalence of coronary heart disease attributed to the surging adoption of a sedentary lifestyle has increased the need for anticoagulants. As per the National Institutes of Health, coronary artery disease affects around 18.2 million American adults, making it the most common heart disease in the U.S. In addition, surging elderly population that is highly susceptible to this disorder will further increase product uptake.
 

North America held approximately 60.5% of the anticoagulants market share in 2022. Growing healthcare spending in the region is positively impacting industry landscape. Moreover, the rising burden of cardiovascular disorders has further increased the need for anticoagulants in the region. North America is also home to major industry players such as Johnson and Johnson, Pfizer, and others focusing on product innovations to extend their footprint.